Last reviewed · How we verify
GSK364735 oral solution and oral tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK364735 oral solution and oral tablets (GSK364735 oral solution and oral tablets) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK364735 oral solution and oral tablets TARGET | GSK364735 oral solution and oral tablets | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK364735 oral solution and oral tablets CI watch — RSS
- GSK364735 oral solution and oral tablets CI watch — Atom
- GSK364735 oral solution and oral tablets CI watch — JSON
- GSK364735 oral solution and oral tablets alone — RSS
Cite this brief
Drug Landscape (2026). GSK364735 oral solution and oral tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk364735-oral-solution-and-oral-tablets. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab